Biotechnology company Calluna Pharma has completed a Phase I clinical study for its lead product candidate targeting inflammatory and fibrotic diseases. 

The company’s lead candidate, CAL101, was shown to have a favorable safety, pharmacokinetic (PK) and immunogenicity profile in the Phase I study. 

CAL101 is a first-in-class mAb that targets S100A4, a damage-associated molecular pattern (DAMP) protein implicated in serious and life-threatening diseases, such as idiopathic pulmonary fibrosis and systemic sclerosis. 

In pre-clinical studies. CAL101 has been shown to prevent and treat fibrosis and modify the disease-specific activation of fibroblasts, which is responsible for driving the progression of fibrosis.  

In this Phase I study, single ascending doses of CAL101 were tested in healthy volunteers and multiple ascending doses were tested in patients with mild to moderate chronic plaque psoriasis. CAL101 was found to have a favorable safety profile and was well tolerated with no Serious Adverse Events across all doses tested. CAL101 also demonstrated a favorable PK profile with dose-dependent increases in exposure, supporting once monthly dosing.  

Jonas Hallén, Co-Founder and Chief Medical Officer of Calluna Pharma, said: “We are encouraged by the findings from the Phase 1 study. These results are an important step forward in the development of our lead asset, CAL101, particularly for fibrotic and fibro-inflammatory diseases where there remains a critical need for innovative therapeutic options. We are excited as we now move into the next phase of clinical development.” 

Next year, Calluna plans to advance CAL101 into Phase 2 studies in fibrotic and fibro-inflammatory indications.